CLINICAL TRIALS PROFILE FOR ATRASENTAN
✉ Email this page to a colleague
Clinical Trials for Atrasentan
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00017264 ↗ | Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma | Completed | National Cancer Institute (NCI) | Phase 1 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma. |
NCT00036543 ↗ | A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer | Completed | Abbott | Phase 3 | This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer. |
NCT00036556 ↗ | Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer | Completed | Abbott | Phase 3 | This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer. |
NCT00038662 ↗ | Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure | Completed | Abbott | Phase 2 | The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective). |
NCT00039429 ↗ | Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally recurrent or metastatic kidney cancer. |
NCT00039429 ↗ | Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer | Completed | Eastern Cooperative Oncology Group | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally recurrent or metastatic kidney cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Atrasentan
Condition Name
Clinical Trial Locations for Atrasentan
Trials by Country
Clinical Trial Progress for Atrasentan
Clinical Trial Phase
Clinical Trial Sponsors for Atrasentan
Sponsor Name